Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe diseasePatient survey findings suggest that clear communication, transparent discussions of potential benefits and
Avalyn Pharma showed computer models suggesting their lung medicine could reach sick lungs well, and patients said they like when companies explain things clearly. When a company shares positive early science, watch if doctors and patients actually believe it will help.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.